Evidence map›Paper›PMID 35343595›Full record

ArticleStatistics in medicine2022

Utility based approach in individualized optimal dose selection using machine learning methods.

Pin Li, Jeremy M G Taylor, Philip S Boonstra, Theodore S Lawrence, Matthew J Schipper

Open access · hybridAbstract read
In one paragraph

Article in Statistics in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Utility-Based Dose Selection for Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma.International journal of radiation oncology, biology, physics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Artificial intelligence uncertainty quantification in radiotherapy applications - A scoping review.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pin LiDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-4508-3762
Jeremy M G TaylorDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Philip S BoonstraDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-8545-9133
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Matthew J SchipperDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-6728-4720
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
TREATMENT VERIFICATION AND TREATMENT PLAN REFINEMENTP01CA059827 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KESSLER, MARC LEWIS, LAWRENCE, THEODORE S · 1993 to 2018
$37.9M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6M
Statistical Methods for Cancer BiomarkersR01CA129102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GHOSH, DEBASHIS, TAYLOR, JEREMY M.G. · 2009 to 2021
$3.3M
NCI NIH HHS P01 CA059827NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA129102NIH HHS CA046592NIH HHS CA059827NIH HHS CA129102
6 · The paper itself

Abstract

The goal in personalized medicine is to individualize treatment using patient characteristics and improve health outcomes. Selection of optimal dose must balance the effect of dose on both treatment efficacy and toxicity outcomes. We consider a setting with one binary efficacy and one binary toxicity outcome. The goal is to find the optimal dose for each patient using clinical features and biomarkers from available dataset. We propose to use flexible machine learning methods such as random forest and Gaussian process models to build models for efficacy and toxicity depending on dose and biomarkers. A copula is used to model the joint distribution of the two outcomes and the estimates are constrained to have non-decreasing dose-efficacy and dose-toxicity relationships. Numerical utilities are elicited from clinicians for each potential bivariate outcome. For each patient, the optimal dose is chosen to maximize the posterior mean of the utility function. We also propose alternative approaches to optimal dose selection by adding additional toxicity based constraints and an approach taking into account the uncertainty in the estimation of the utility function. The proposed methods are evaluated in a simulation study to compare expected utility outcomes under various estimated optimal dose rules. Gaussian process models tended to have better performance than random forest. Enforcing monotonicity during modeling provided small benefits. Whether and how, correlation between efficacy and toxicity, was modeled, had little effect on performance. The proposed methods are illustrated with a study of patients with liver cancer treated with stereotactic body radiation therapy.

Indexed as

Machine LearningBiomarkersComputer SimulationHumansNormal DistributionTreatment OutcomeBiomarkersGaussian processrandom forestutility matrix

Identifiers

PMID35343595
PMCPMC9233043
OpenAlexW4221101502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.